Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GLP1R | P43220 | 8/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.35 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.34 |
| ▸ | TLR2 | O60603 | 4/20 | 0.34 |
| ▸ | RRM1 | P23921 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15503622 | 0.92 | MEN1 (0.40) | MEN1KMT2AGLP1RDPP7NOD1 | |
| SCHEMBL14501539 | 0.87 | DPP7 (0.41) | GLP1RDPP7NOD1TLR2RRM1 | |
| SCHEMBL15503547 | 0.85 | MEN1 (0.40) | MEN1KMT2AGLP1RDPP7NOD1 | |
| SCHEMBL15503621 | 0.83 | MEN1 (0.45) | MEN1KMT2AGLP1RALDH1A1CA2 | |
| SCHEMBL15503581 | 0.83 | MEN1 (0.47) | MEN1KMT2ADPP7TLR2CA2 | |
| SCHEMBL15503575 | 0.81 | GLP1R (0.46) | MEN1KMT2AGLP1RTLR2 | |
| SCHEMBL25708285 | 0.80 | MEN1 (0.46) | MEN1KMT2AGLP1RDPP7NOD1 | |
| SCHEMBL25835481 | 0.79 | DPP7 (0.47) | MEN1KMT2AGLP1RDPP7NOD1 | |
| SCHEMBL26032521 | 0.76 | DPP7 (0.45) | MEN1KMT2AGLP1RDPP7NOD1 | |
| SCHEMBL15503578 | 0.76 | MEN1 (0.49) | MEN1KMT2ADPP7TLR2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140072513-A1 | SUGAR AND PEG FUNCTIONALIZED POLYACETALS WITH CONTROLLED PH-DEPENDENT DEGRADATION | ARGON PHARMA S.L. (ES) | 2014-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140072513-A1 | SUGAR AND PEG FUNCTIONALIZED POLYACETALS WITH CONTROLLED PH-DEPENDENT DEGRADATION | CD44, PGD, H1-3 | MEN1 2068/4885KMT2A 2589/4885GLP1R 2262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.